KR101860487B1 - N-[4-(1-시클로부틸 피페리딘-4-일옥시) 페닐]-2-(모르폴린-4-일) 아세트아미드 디히드로클로리드의 대규모 생산을 위한 방법 - Google Patents

N-[4-(1-시클로부틸 피페리딘-4-일옥시) 페닐]-2-(모르폴린-4-일) 아세트아미드 디히드로클로리드의 대규모 생산을 위한 방법 Download PDF

Info

Publication number
KR101860487B1
KR101860487B1 KR1020177005182A KR20177005182A KR101860487B1 KR 101860487 B1 KR101860487 B1 KR 101860487B1 KR 1020177005182 A KR1020177005182 A KR 1020177005182A KR 20177005182 A KR20177005182 A KR 20177005182A KR 101860487 B1 KR101860487 B1 KR 101860487B1
Authority
KR
South Korea
Prior art keywords
hours
yloxy
cyclobutylpiperidin
phenyl
morpholin
Prior art date
Application number
KR1020177005182A
Other languages
English (en)
Korean (ko)
Other versions
KR20170036044A (ko
Inventor
라마크리쉬나 니로기
아닐 카르바리 쉰데
라마사스트리 캄밤파티
벤카테스와를루 자스티
Original Assignee
수벤 라이프 사이언시스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수벤 라이프 사이언시스 리미티드 filed Critical 수벤 라이프 사이언시스 리미티드
Publication of KR20170036044A publication Critical patent/KR20170036044A/ko
Application granted granted Critical
Publication of KR101860487B1 publication Critical patent/KR101860487B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177005182A 2014-08-16 2014-10-20 N-[4-(1-시클로부틸 피페리딘-4-일옥시) 페닐]-2-(모르폴린-4-일) 아세트아미드 디히드로클로리드의 대규모 생산을 위한 방법 KR101860487B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4010/CHE/2014 2014-08-16
IN4010CH2014 2014-08-16
PCT/IN2014/000666 WO2016027275A1 (en) 2014-08-16 2014-10-20 Process for large scale production of n-[4-(1- cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acet amide dihydrochloride

Publications (2)

Publication Number Publication Date
KR20170036044A KR20170036044A (ko) 2017-03-31
KR101860487B1 true KR101860487B1 (ko) 2018-05-23

Family

ID=52339255

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005182A KR101860487B1 (ko) 2014-08-16 2014-10-20 N-[4-(1-시클로부틸 피페리딘-4-일옥시) 페닐]-2-(모르폴린-4-일) 아세트아미드 디히드로클로리드의 대규모 생산을 위한 방법

Country Status (28)

Country Link
US (1) US9802896B2 (ja)
EP (1) EP3180334B1 (ja)
JP (1) JP6385580B2 (ja)
KR (1) KR101860487B1 (ja)
CN (1) CN106573925B (ja)
AP (1) AP2017009753A0 (ja)
AU (1) AU2014403999B2 (ja)
BR (1) BR112017002922B1 (ja)
CA (1) CA2957494C (ja)
CY (1) CY1121253T1 (ja)
DK (1) DK3180334T3 (ja)
EA (1) EA032823B1 (ja)
ES (1) ES2693378T3 (ja)
HK (1) HK1231472A1 (ja)
HR (1) HRP20181801T1 (ja)
HU (1) HUE041465T2 (ja)
IL (1) IL250412B (ja)
LT (1) LT3180334T (ja)
MX (1) MX364931B (ja)
NZ (1) NZ728915A (ja)
PL (1) PL3180334T3 (ja)
PT (1) PT3180334T (ja)
RS (1) RS57927B1 (ja)
SG (1) SG11201701104SA (ja)
SI (1) SI3180334T1 (ja)
TR (1) TR201816175T4 (ja)
WO (1) WO2016027275A1 (ja)
ZA (1) ZA201700936B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019229509A1 (en) * 2018-05-31 2019-12-05 Suven Life Sciences Limited Method of treatment with histamine-3 receptor inverse agonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114348A1 (en) * 2011-02-23 2012-08-30 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
CN103415510B (zh) * 2011-02-04 2016-01-13 庵原化学工业株式会社 氨苯基嘧啶基醇衍生物的制备方法及其合成中间体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114348A1 (en) * 2011-02-23 2012-08-30 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands

Also Published As

Publication number Publication date
IL250412A0 (en) 2017-03-30
JP6385580B2 (ja) 2018-09-05
ES2693378T3 (es) 2018-12-11
WO2016027275A1 (en) 2016-02-25
CA2957494A1 (en) 2016-02-25
MX364931B (es) 2019-05-14
US20170260135A1 (en) 2017-09-14
EP3180334A1 (en) 2017-06-21
LT3180334T (lt) 2018-11-12
EA201790388A1 (ru) 2017-06-30
HRP20181801T1 (hr) 2018-12-28
PT3180334T (pt) 2018-11-16
JP2017525761A (ja) 2017-09-07
BR112017002922B1 (pt) 2023-01-03
BR112017002922A2 (pt) 2017-12-05
CN106573925B (zh) 2020-04-10
ZA201700936B (en) 2019-07-31
MX2017002043A (es) 2017-05-04
DK3180334T3 (en) 2018-11-26
HUE041465T2 (hu) 2019-05-28
SI3180334T1 (sl) 2019-01-31
RS57927B1 (sr) 2019-01-31
HK1231472A1 (zh) 2017-12-22
AU2014403999A1 (en) 2017-02-23
AU2014403999B2 (en) 2017-12-14
IL250412B (en) 2019-11-28
PL3180334T3 (pl) 2019-03-29
AP2017009753A0 (en) 2017-02-28
KR20170036044A (ko) 2017-03-31
EP3180334B1 (en) 2018-09-26
SG11201701104SA (en) 2017-03-30
TR201816175T4 (tr) 2018-11-21
US9802896B2 (en) 2017-10-31
CN106573925A (zh) 2017-04-19
NZ728915A (en) 2018-01-26
CA2957494C (en) 2018-08-28
CY1121253T1 (el) 2020-05-29
EA032823B1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
TWI454471B (zh) 製備細胞凋亡促進劑之方法
JP2021035947A (ja) ブルトンチロシンキナーゼ阻害剤の合成
EP3060551B1 (en) Process for the preparation of a pde4 inhibitor
EP2970263B1 (en) Processes for the preparation of an apoptosis-inducing agent
JP6151453B2 (ja) 1−[(2−ブロモフェニル)スルホニル]−5−メトキシ−3−[(4−メチル−1−ピペラジニル)メチル]−1h−インドールジメシラート一水和物の大規模合成法
US11542245B2 (en) Preparative process
CN110799503A (zh) 美卡奥美坎替的合成
JP6454707B2 (ja) trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成
WO2012004391A1 (en) Process for the preparation of flupirtine maleate
KR101860487B1 (ko) N-[4-(1-시클로부틸 피페리딘-4-일옥시) 페닐]-2-(모르폴린-4-일) 아세트아미드 디히드로클로리드의 대규모 생산을 위한 방법
TWI534126B (zh) 用於製備吡唑羧酸醯胺之方法
KR101085170B1 (ko) (s)-리바스티그민의 제조방법
CN108033902A (zh) 一种高纯度贝利司他顺式异构体的制备方法
CN105712920B (zh) 一种维格列汀的制备方法
NO311935B1 (no) Nye heteroaryloksyetylaminer, anvendelse, fremgangsmåte for fremstilling derav og farmasöytiske preparater inneholdende dem
CN115650935A (zh) 一种高哌嗪衍生物的高纯制备方法
CN116217522A (zh) Glp-1受体激动剂关键中间体的手性纯化方法
JPH0119378B2 (ja)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant